4.4 Article

Effects of grape seed proanthocyanidin on Alzheimer's disease in vitro and in vivo

Journal

EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 12, Issue 3, Pages 1681-1692

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2016.3530

Keywords

Alzheimer's disease; grape seed proanthocyanidin; oxidative stress; A precursor protein; tau protein; presenilin-1

Funding

  1. Special Funds from Central Finance of China in Support of the Development of Local Colleges and University [276 (2014)]
  2. BannerBio Nutraceuticals, Inc.

Ask authors/readers for more resources

Grape seed proanthocyanidin (GSPA) consists of catechin, epicatechin and epicatechin gallate, which are strong antioxidants that are beneficial to health and may attenuate or prevent Alzheimer's disease (AD). In the present study, the effects of GSPA on pheochromocytoma (PC12) cell viability were determined using cell counting kit-8 and lactate dehydrogenase (LDH) assays, whereas apoptosis and mitochondrial membrane potential (m) were measured via flow cytometry analysis. The effect of GSPA administration on the behavior and memory of amyloid precursor protein (APP)/presenilin-1 (PS-1) double transgenic mice was assessed using a Morris water maze. APP A peptides and tau hyperphosphorylation were examined by western blotting; whereas the expression levels of PS-1 were evaluated by reverse transcription-quantitative polymerase chain reaction and compared with pathological sections stained with hematoxylin-eosin and Congo red. Data from the in vitro experiments demonstrated that GSPA significantly alleviated A25-35 cytotoxicity and LDH leakage ratio, inhibited apoptosis and increased m. The findings from the in vivo experiments showed a significant enhancement in cognition and spatial memory ability, an improvement in the pathology of APP and tau protein and a decrease in PS-1 mRNA expression levels. Therefore, the results of the present study indicated that GSPA may be a novel therapeutic strategy for the treatment of AD or may, at the very least, improve the quality of life of patients with AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available